2nd Advance-HTA Capacity Building Workshop

Warsaw, Poland, 24-25 September 2015


The application of HTA has expanded into Eastern Europe and its uptake has increased over the past few years. Some countries have extended the use of HTA to support rational and transparent spending decisions, while others, such as Poland, use it as an explicit criterion for setting the price and/or reimbursement of medicines. Slovenia is actually in the process of developing an HTA system.

There is no doubt that many advances have been made in the recent years in Europe regarding the implementation of HTA. Yet, in many Member States, particularly in South & Eastern Europe, HTA is still in a nascent phase and much can be done to inform local decision-makers about uses of HTA in different setups.

The Advance-HTA Capacity Building Workshop was therefore an opportunity to build HTA capacity, outline the options available for decision-makers and debate the actions required for this purpose, tailor-made for the needs of the countries in this region.


  • Undertake HTA capacity building in South & Eastern Europe
  • Present the HTA methodological advances developed by the Advance HTA Consortium
  • Discuss the relevance of such methodological advances with local participants from South & Eastern Europe
  • Discuss future developments in HTA and their policy implications
  • Foster international collaboration and create a network for exchange of expertise.

The workshop took place in Warsaw, Poland, on 24-25 September 2015. It was organised by Advance-HTA with additional support from Agency for Health Technology Assessment and Tarif System in Poland (Agencja Oceny Technologii Medycznych i Taryfikacji - AOTMiT).

The workshop was attended by 57 participants, mainly policy makers working in public institutions such as Ministries of Health, Health Insurance Funds, Social Security Institutes and HTA Agencies. In total, 14 countries were represented: Bulgaria, Czech Republic, Denmark, Estonia, Greece, Hungary, Latvia, Lithuania, Moldova, Poland, Russia, Slovenia, the Ukraine and the UK.

Agenda and Resources

The 2-day workshop included 6 sessions:

  • Assessing Value for Money
  • Value Assessment in Health Technology
  • Using Alternative Methods to Assess Value of New Medical Technologies
  • HTA and Rare Disease: Assessing the Societal Value of Orphan Drugs
  • HTA and Medical Devices
  • Strengthening and Implementing HTA in Emerging Settings

Click here to access the full program.

All presentations delivered during the workshop are provided below:

How Can Value for Money Be Assessed?

Why Do Some Countries Approve a Cancer Drug and Others Don't?

Using Multiple-Criteria Decision Analysis: Conceptual Framework and Model

MCDA Application: Empirical Evidence

HTA and Rare Diseases: Assessing the Societal Value of Orphan Drugs

Preference elicitation: who can do it? - theoretical foundations

Preference elicitation: who can do it? - preliminary results

HTA & QoL Measurement

The Importance of HTA in Emerging Settings

HTA and Medical Devices


Based on feedback received from participants, the workshop was a success in terms of quality of speakers, program's structure and content, and general workshop's administration. In fact, more than 85% stated the workshop met their expectations and 100% would recommend the workshop to colleagues.

More of this type of workshop please

The group work was beneficial and effective!

The workshop was very useful - especially to someone new to HTA.

Full title Advancing and strengthening the methodological tools and policies relating to the application and implementation of Health Technology Assessment (HTA)
Project number 305983
CoordinationLSE Health
Consortium 13 partners

The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/2007-2013 under grant agreement No. 305983.